Payer Objection Patterns
Common objections heard on tier-3 peer-to-peer calls. Win rates by payer and denial reason are not static — see the live dashboard for the current breakdown.
| Objection | Typical payer rationale | Counter-direction |
|---|---|---|
| Step therapy not met | "Patient must fail preferred formulary agents before the requested drug is approved." | Anchor Monitoring: confirmed drug-by-drug, dose-by-dose trial history with dates of discontinuation and documented reason (intolerance, contraindication, lack of efficacy). FDA label and society guidelines may explicitly carve out cases where step therapy is inappropriate. |
| Insufficient functional / ischemic evidence | "Symptoms could be explained by non-cardiac etiology; further functional testing required." | Anchor Symptom + Anatomy: pre-test probability, prior stress or imaging findings, documented symptom burden (CCS class, exercise capacity, ischemic ECG changes). Cite the requesting indication and the AHA/ACC AUC for the requested modality. |
| Off-label indication not supported | "Requested use is off-label; payer medical policy does not list the indication." | Anchor Risk + Timeline: cite compendia, peer-reviewed evidence, FDA prescribing information for the requested indication, and the absence of on-label alternatives. Document the patient's specific clinical context. |
| Site-of-service mismatch | "In-office or outpatient setting is appropriate; hospital-based infusion/imaging is not medically necessary." | Anchor Anatomy + Risk: clinical factors that require hospital-level staffing, monitoring, or rescue capability (anesthesia risk, contrast reaction history, infusion reaction protocol, hemodynamic monitoring requirements). |
| Frequency / dosing exceeds policy | "Requested interval or dose is more frequent / higher than the payer policy limit." | Anchor Timeline + Monitoring: documented disease activity (lab values, imaging markers, functional scores) that justifies the intensification. Cite FDA label dosing and society guideline escalation criteria. |
| Requested imaging duplicates prior study | "Comparable study performed within the last 12 months — repeat is not warranted." | Anchor Timeline + Symptom: progression of symptoms since prior study, change in clinical status, prior study limitations, and the clinical decision the new study is intended to answer. |
SMART Clinical Evidence Anchors by Indication
For each indication, the SMART anchors our team confirms are documented pre-call. The SMART framework is VCS's own scoring rubric; clinical thresholds and dosing are anchored to named society guidelines and FDA prescribing information.
CT Angiography — Coronary CTA
Pre-call check: confirm pre-test probability, prior non-invasive testing, and the specific clinical question the CTA is intended to answer.
S
Symptom
Angina class (CCS grading), symptom duration, exertional vs. resting pattern.
M
Monitoring
Prior stress result, calcium score if available, ECG findings.
A
Anatomy
Stenosis severity / location, plaque characterization on prior imaging (if any).
R
Risk
Pre-test probability of CAD, ASCVD risk score, modifiable risk factors.
T
Timeline
Symptom progression, dates of prior testing, prior ED / urgent visits.
Source: AHA/ACC 2021 Chest Pain Guideline; ACC/AHA Appropriate Use Criteria for stable chest pain.
Cardiac MRI — Stress CMR / Viability
Pre-call check: confirm the indication (ischemia evaluation vs. viability / scar characterization), prior echo / nuclear results, and the question the study addresses.
S
Symptom
Heart-failure class (NYHA), symptomatic arrhythmia, ischemic symptom burden.
M
Monitoring
Prior echo parameters, nuclear perfusion findings, biomarker trends.
A
Anatomy
Infarct vs. viable myocardium, LGE pattern, regional wall motion.
R
Risk
LVEF, arrhythmia risk, procedural risk of alternative invasive study.
T
Timeline
Time since index event, prior revascularization dates, prior imaging dates.
Source: SCMR 2020 Clinical Consensus; AHA/ACC Appropriate Use Criteria for ischemic heart disease.
Biologic Infusion Medications (by drug class)
Pre-call check: confirm the diagnosis with severity criteria, prior conventional-therapy trial history (drug + duration), and the clinical venue appropriate for the requested infusion.
S
Symptom
Diagnosis with disease-specific severity criteria (e.g. DAS28/CRP for RA, PASI for psoriasis, disease activity scores per indication).
M
Monitoring
Lab / biomarker evidence (acute-phase reactants, disease-specific markers), prior imaging where applicable.
A
Anatomy
Disease distribution and organ involvement relevant to the requested biologic.
R
Risk
Infusion-site appropriateness, anaphylaxis / hypersensitivity protocols, infection-risk screening (TB, hepatitis) per FDA label.
T
Timeline
Re-induction or maintenance schedule, infusion-date authority, prior biologic exposure and outcomes.
Source: FDA prescribing information for the specific requested agent; ACR and NPF guideline recommendations.
P2P Call-Flow Script
The seven-step flow our clinical team and reps run on a tier-3 P2P. Scripts below are illustrative framings — adapt to the documented patient evidence.
- Pre-call chart review checklistSMART anchors confirmed, dates and source documents identified, prior payer denials reviewed, contacting physician briefed on objection patterns.
- Opening — verify reviewer + case IDsConfirm the reviewing physician's name, the case reference, member ID, and the date of service under review before stating the case.
- State the case in one sentenceOne-sentence framing of the diagnosis, the specific service under review, and why this is the appropriate next step.
- Walk S → M → A → R → TOne sentence per anchor. Lead with symptom and anatomy; close on risk and timeline. Cite the source guideline or FDA label where it directly answers the payer's likely objection.
- Handle objectionsUse the objection → response table below. Restate the relevant anchor with documented evidence; do not introduce new clinical claims live on the call.
- Close with an explicit ask"Approve for the requested dates / dose / site of service." If the reviewer is non-decisional, request the case be advanced and confirm the callback window.
- Post-call documentationLog the call in
p2p_calls, write outcome + reviewer notes intoworkflow_transitionson the auth_request, and updatep2p_outcome. Carry forward any reviewer commitments to the next workflow stage.
Example Framing — Q&A
Adapt to your patient's documented evidence; do not introduce new clinical claims live.
"Why coronary CTA rather than a stress test?"
Patient has documented intermediate pre-test probability with an equivocal prior stress result. CTA is appropriate per ACC/AHA AUC to characterize anatomy and clarify the need for invasive coronary angiography.
Illustrative framing — adapt to the specific prior stress modality and result documented in the chart.
"Why a biologic infusion rather than a step-up oral agent?"
Patient has documented trial-and-failure of conventional therapy (drug, dose, duration, reason for discontinuation). Severity and disease activity at this visit meet the criteria in the FDA prescribing information for the requested biologic. Oral step-up is no longer clinically appropriate.
Illustrative framing — anchor to the specific oral agents and discontinuation reasons documented in the chart.
"Why is site-of-service hospital-based rather than outpatient?"
Patient has documented clinical factors that warrant hospital-level monitoring or rescue capability during the infusion / study: prior reaction history, hemodynamic monitoring requirements, or anesthesia need per the requesting department.
Illustrative framing — anchor to the specific patient risk factor documented in the chart and the requesting department's protocol.
"Can you do this closer to home / in network?"
Network adequacy and geographic access can be addressed administratively post-clinical approval; the current call is to confirm medical necessity. Once approved, our team coordinates the in-network venue and updates the case.
Illustrative framing — used when the reviewer raises network / venue before reaching a medical-necessity decision.
Objection → Response Map
When the reviewer objects during the call, anchor to the documented evidence before introducing anything new.
| Objection | Response direction |
|---|---|
| "Step therapy not met." | Walk through documented conventional-therapy trials with drug, dose, duration, and reason for discontinuation. Cite FDA label or society guideline if it carves out this case. |
| "Insufficient evidence of ischemia / disease activity." | Anchor on Symptom + Monitoring: prior testing results, severity scores, biomarker trends on file. |
| "Not medically necessary at this site / frequency." | Anchor on Risk + Timeline: cite the patient-specific factor that mandates the requested setting or interval. |
| "Records are not sufficient." | Offer to have the requesting physician walk the specific finding on the call. Avoid promising to send records that do not yet exist. |
| "Reviewer cannot decide / will need to escalate." | Confirm the escalation path, request a callback window, and document the reviewer name + commitment in the call note. |
Paired With Your Live Denial Intelligence
This playbook is editorial — for real-time win rates by payer and denial reason, use the live dashboards.
Live data
Denial Defense Analytics
Payer × denial-reason patterns, SMART clinical factors correlated with successful appeals, and ranked denial reasons from VCS-supported cases.
Open the live dashboard →
CPT intelligence
CPT Denial Defense Library
CPT-code-level defense patterns, required documentation, payer-specific criteria, and ready-to-use appeal templates.
Open the Defense Library →